ArticleWorld journal of biological chemistry2026
Dual function of transforming growth factor beta 2 in the progression of gastric carcinoma.
Article in World journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been reported that transforming growth factor beta (TGFβ) might play an important role for the development of various types of carcinomas. TGFβ is produced from not only cancer cells but also stromal cells such as fibroblasts. Controversial functions of TGFβ for tumor progression such as tumor suppression and progression has been widely recognized. TGFβ has 3 subtypes including TGFβ1, TGFβ2, and TGFβ3. The role of TGFβ1 and TGFβ3 for gastric carcinoma (GC) progression has been well-known, but that of TGFβ2 remains to be unknown.
aimTo clarify the significance of TGFβ2 in the development of GC.
methodsImmunohistochemical analysis of GC was performed to clarify the clinical function of TGFβ2 on the progression of GC by evaluating TGFβ2 expression on both cancer cells and cancer-associated fibroblasts (CAFs) using 518 GC specimens.
resultsHigh TGFβ2 expression in cancer cells was significantly correlated with T factor and stage, but not with vascular invasion and lymphatic invasion. In contrast, TGFβ2 expression on CAFs was significantly correlated with lymph node metastasis and vascular invasion, but not with the T factor. Five-year survival of patients with TGFβ2-high on cancer cells and -low on CAFs was significantly worse in compared to the other group These findings suggest that TGFβ2 might play differential roles between cancer cells and CAFs in the development of GC.
conclusionTGFβ2 on cancer cells might stimulates the cancer proliferation and invasion, but not TGFβ2 on CAFs. TGFβ2 high on cancer cells and low on CAF or others might be a promising prognostic factor for patients with GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.